logo
Harlem residents accuse NYC of shirking life-saving inspections amid deadly Legionnaires' disease outbreak: ‘Irresponsible'

Harlem residents accuse NYC of shirking life-saving inspections amid deadly Legionnaires' disease outbreak: ‘Irresponsible'

Yahoo6 hours ago
The deadly Legionnaires' outbreak gripping Harlem has city officials in hot water — as locals accused them Friday of dropping the ball on life-saving inspections and needlessly slow-walking revealing exactly where the disease hit.
Many outraged Harlem residents told The Post they only learned that they lived or worked in one of 10 buildings with cooling towers that tested positive for the insidious Legionnaires'-causing bacterium after the list was unveiled Thursday — weeks into the outbreak that has killed four people.
'Why weren't these cooling towers properly maintained? Who dropped the ball and why?' raged Nichole Ingram, who fell ill with Legionnaires' disease around July 24 after she attended a funeral service in 2239 Adam Clayton Powell Jr. Blvd, one of the affected buildings.
Ingram, 53, said her son Raymond, an asthmatic 35-year-old, was still hospitalized with the flu-like, respiratory illness in New York-Presbyterian Hospital after a stay in Harlem Hospital — one of several city-owned buildings with affected cooling towers.
'Why buildings in Harlem and not in lower Manhattan? People are losing their lives unnecessarily,' she said.
The outbreak comes amid a drop in cooling tower inspections.
Only roughly 1,200 cooling towers were inspected for Legionnaires' bacteria during the first six months of this year, compared to nearly 5,100 at the same point in 2017, data provided by the city Department of Health shows.
Building owners by law are required to test for the disease-causing bacteria Legionella every 90 days to avoid outbreaks.
Four New Yorkers have died in the current outbreak and 17 remain hospitalized out of 99 confirmed cases, DOH officials said Thursday.
Officials that day also finally released — after weeks of only providing five ZIP codes — the addresses of the buildings with the 12 total cooling towers that tested positive for Legionella.
All but one of the 10 buildings were either behind on the mandated testing or had cooling towers that weren't checked at all this year, according to Gothamist.
In addition to Harlem Hospital, the city-owned buildings with affected cooling towers were Central Harlem Sexual Health Clinic, the NYC Economic Development Corporation and CUNY's Marshak Science Building, the DOH said.
Health Commissioner Michelle Morse argued the city withheld the building addresses to help keep all New Yorkers vigilant, regardless of where they live.
'We did not want people to think, well, I don't live there, I don't have to worry,' she said.
But New Yorkers who live and work in the buildings were horrified after the last-minute revelation — with some only hearing it from The Post on Friday.
'You're going to a hospital for a care and there's a possibility you're getting sick because of the lack of inspections?' asked Mariela L. 57, who was visiting a family member at Harlem Hospital.
'That's irresponsible on the city's part. To my knowledge, they did not inform the patients before the news broke. My family member found out from me and I found out from the news.'
A manager at GNC Live Well in 215 West 125th Street, an affected building also with medical offices and a bank, said he didn't know until Friday.
'Nobody from the building told us anything,' he said. 'We're the last to find out. We find out when the damage is done, the ship is sinking.'
Legionnaires' bacteria is found in freshwater and can grow in water systems such as those used for air conditioning large buildings, especially during warmer weather.
Mist released by the cooling towers can send the bacteria into the air, and if inhaled, it can cause Legionnaires' disease, a severe form of pneumonia.
The last wave of Legionnaires' this rampant hit the Big Apple a decade ago — and prompted the cooling tower inspection law.
In summer 2015, toxic cooling towers at the Opera House Hotel infected more than 100 and killed 12 in the South Bronx, following a smaller outbreak in Co-op City earlier that year.
But despite the legislation requiring regular testing, another widespread outbreak hit Washington Heights in upper Manhattan in 2018, killing one person and sickening 60 others.
Councilwoman Julie Menin (D-Manhattan), who sits on the body's health committee, promised a 'hard-hitting hearing' in September over the health department's failures in the most recent outbreak.
'I think it's unconscionable that we have a department of health with a staffing vacancy rate hovering around 9%,' she said.
'And that the city wouldn't even initially disclose the locations of the cooling towers that tested positive even though multiple locations — four of them in fact — were city owned buildings. We clearly needed faster and more transparent government response to legionnaires that keeps New York are safe.'
State Sen. Cordell Cleare (D-Manhattan) questioned why the outbreak was concentrated in Harlem.
'Surely, the Legionella bacteria do not have a special affiliation with our neighborhood?' she said.
'We question why it only seems to be in this area. We do not want to be the canaries in the coal mine.'
Ingram's lawyer, Jory Lange, is representing 31 patients in the latest Legionnaires' outbreak and will likely be filing a lawsuit when the actual source of the outbreak is identified.
Lange said simple maintenance, akin to using chlorine to clean a pool, is all that's needed to keep Legionnaires' at bay.
'A Legionnaires' outbreak should not be happening in 2025. We're seeing this every summer in New York,' he said.
'People are breaking the law.'
— Additional reporting by Georgett Roberts, Matthew Fischetti, Vaughn Golden and Craig McCarthy
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

From Home Visits to Health Victories: Global Health Tech Gets Personal
From Home Visits to Health Victories: Global Health Tech Gets Personal

Yahoo

time6 minutes ago

  • Yahoo

From Home Visits to Health Victories: Global Health Tech Gets Personal

Meet the health workers using tech to overcome deadly diseases NORTHAMPTON, MA / / August 19, 2025 / "Thank you so much for coming to my home. You saved my life." Those simple words from Bill Adams* spoke volumes to Karen Fernandez, one of the original community health workers with an in-home healthcare program called Healthy Neighbor in Camden, New Jersey. A few days before, she had met Bill for the first time at his home and discovered that his blood pressure was incredibly high. She called the triage line and was able to get him into the emergency department the same day. Before that first visit, Bill called Karen to ask if she was really going to show up. He didn't have health insurance or much trust in the healthcare system that had let him down so many times before. Karen did show up - the first step in creating trust and a foundation toward Bill's future health. "That's why I do this job," said Fernandez. "It's rewarding. If you can make an impact on a person's life, they will never forget it." This is just one of hundreds of stories illustrating the impact that the four community health workers who comprise Healthy Neighbor are bringing to the Camden community. They are equipped with a technology platform called SPICE from Medtronic LABS, which develops community-based, tech-supported healthcare solutions for underserved communities. This digital tool streamlines their work by capturing basic healthcare needs, tracking blood pressure and glucose over time, and flagging elevated readings for follow-up. This helps link community and health system care, reduces paperwork, and allows the community health workers to focus on their patients. Bringing a global program home Camden, a city of about 70,000 people across the Delaware River from Philadelphia, has a life expectancy gap of as much as 16 years compared to neighborhoods just 6.5 miles away.[i] The rates of diabetes and high blood pressure are dramatically higher than in nearby communities. Virtua Health is South Jersey's largest healthcare provider, and many of its patients live in Camden. When leadership at Virtua saw these staggering health statistics, they felt compelled to do something. "Our mission is to help our community be well, get well, and stay well. We take it very seriously," said Dan Master, the director of community health and impact at Virtua. "And there is a lot of alignment with Medtronic LABS and Medtronic in this." For over a decade, Medtronic LABS has built community-based, tech-enabled solutions to address healthcare disparities around the world. But they had never built a program in the United States. Until Virtua called. "When we first met with Virtua, we knew this was a great opportunity to bring our learnings from community-based care models in Asia and Africa to the U.S. and continue to innovate," said Lauren Leccese, head of U.S. programs at Medtronic LABS. "The shared values and commitment to health equity across our organizations created a strong foundation as we started to build the program." From pilot to expansion In August 2023, Medtronic LABS and Virtua launched Healthy Neighbor. The goal was to improve health outcomes through a home visiting program where community health workers provide integrated health and social care for patients living with high blood pressure and/or type 2 diabetes. And it's working. The data from the first two years of the program is in - and it's remarkable: 74% of patients with uncontrolled hypertension achieved meaningful improvement (15-point mean drop in systolic blood pressure) 69% of patients with uncontrolled diabetes achieved meaningful improvements (1.2% mean drop in A1C) These numbers are so impressive that the program is expanding. Virtua received a grant from the city of Camden to grow the community health worker team and reach more patients. "We all had high standards and high hopes for the program when it started, and it's been living up to them," said Alexis Nieves, a Healthy Neighbor community health worker who has been with the program from the beginning. "And these results are not just because of us, but because the patients are willing to make changes as well." More than the numbers The impact of Healthy Neighbor goes beyond data. Patients are enrolled in the program because of either uncontrolled high blood pressure or diabetes (or both), but the care they receive goes far beyond treating those conditions. "It's not normal for a medical team to go out of their way to help you," said Greg Ashton*, a Healthy Neighbor patient. "They're going above and beyond their duty, for someone that they don't even know." There are many factors that influence a person's health, and community health workers are skilled at addressing all of them. They help their patients secure housing, healthy food, heat, and mental-health support. They provide education on nutrition, teach patients to monitor their blood pressure and glucose levels, remind them about upcoming appointments, and help them find transportation to the appointments. "La Shawn is a positive influence on my life, she motivates me," said Denise Manlius, a Healthy Neighbor patient, of her community health worker. "She makes sure that I take my medications. She calls to remind me of appointments. She helped me change my eating habits. Since she's been in my life, my A1C (blood sugar) went down. And it's not just a paycheck to her; she really cares about her people." 'Someone cared enough' "A lot of patients just need to know someone cared enough," said La Shawn Dutton-Spruill. "To show them how to fill up their pillbox until they understand how to do it themselves. To help them understand that their meds will be green this month and white next month, but that it's still the same medication." Due to the program's success and a desire to replicate it to help more patients across the country, Virtua and Medtronic LABS created a toolkit that other health systems can use to establish Healthy Neighbor programs in their communities. The goal is to help more healthcare systems address health disparities and make a meaningful difference in the health of their patients and communities. As Fanny Ochoa, a community health worker with Healthy Neighbor, explained, "It's not just what you do when you're with the patient. The reward is seeing your patients continue to make changes after you leave. The goal of our work is to create a better lifestyle and a better outcome for our patients, beyond the time that we are with them." *Names changed to protect patient privacy Learn more about how Medtronic LABS develops community-based, tech-enabled solutions for underserved patients, families, and communities across the world. View additional multimedia and more ESG storytelling from Medtronic on Contact Info:Spokesperson: MedtronicWebsite: info@ SOURCE: Medtronic View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift

Yahoo

time6 minutes ago

  • Yahoo

Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift

Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company's largest shareholder. The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business. The medtech giant is scheduled to host an Investor Day in mid-2026, as first reported by The Wall Street reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23. 'We're confident and well-positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers,' said Geoff Martha, Medtronic chairman and CEO. Cardiovascular Portfolio revenue of $3.285 billion increased 9.3% as reported and 7.0% organic, with a high-single digit increase in Cardiac Rhythm & Heart Failure, mid-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis. Neuroscience Portfolio revenue of $2.416 billion increased 4.3% reported and 3.1% organic, with a high-single digit increase in Neuromodulation and mid-single digit increase in Cranial & Spinal Technologies, offset by a low-single digit decrease in Specialty Therapies. View more earnings on MDT Medical Surgical Portfolio revenue of $2.083 billion grew 4.4% as reported and 2.4% organic, with low-single digit organic growth in both Surgical & Endoscopy and Acute Care & Monitoring. Diabetes business revenue of $721 million increased 11.5% as reported and 7.9% organic. Outlook Medtronic reiterates its fiscal year 2026 organic revenue growth guidance of 5%. The company revised its fiscal 2026 revenue growth on a reported basis from 4.8%-5.1% to 6.5%-6.8%. It raised sales guidance from $35.15 billion-$35.25 billion to $35.72 billion-$35.82 billion versus the consensus of $35.32 billion. Excluding the potential impact from tariffs, Medtronic expects underlying fiscal 2026 adjusted EPS growth to be approximately 4.5% versus the prior guidance of approximately 4%. Including the reduced potential impact from tariffs of approximately $185 million versus the prior range of roughly $200 million to $350 million, Medtronic raised its fiscal 2026 adjusted earnings to $5.60-$5.66 from the prior range of $5.50-$5.60 versus the consensus of $5.55. In July, a federal appeals court sided with Medtronic in a long-running patent dispute, reversing a jury's finding that the company induced infringement of a Colibri Heart Valve LLC patent related to the implantation of artificial heart valves. Price Action: MDT stock is trading lower by 2.00% to $90.95 premarket at last check Tuesday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MEDTRONIC (MDT): Free Stock Analysis Report This article Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Yahoo

time36 minutes ago

  • Yahoo

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors. Douglas Williams, Ph.D., brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). He has contributed to the development of several blockbuster therapies, including Enbrel®, Tecfidera® and Spinraza®. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences. Dr. Williams currently serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics. Adam Craig, M.D., Ph.D., is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma leading to the approval and commercialization of Vonjo®. He is currently Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). Dr Craig previously held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals and currently serves on the board of Stratus Therapeutics. Dr. Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School. "Doug and Adam are highly accomplished leaders whose deep expertise across R&D, commercialization, and corporate strategy will be invaluable as we advance our development candidates, EGEN-2784 for kidney failure and EGEN-5784 for liver failure, into the clinic," said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. "Their guidance will be invaluable as we advance into the next phase of growth as a clinical-stage company focused on our mission to transform the treatment of organ failure." "eGenesis is developing truly pioneering solutions for one of the most pressing unmet needs in medicine," said Dr. Williams. "The combination of cutting-edge genetic engineering, rigorous science, and a mission-driven team positions eGenesis to deliver breakthroughs that could fundamentally change the field of organ transplantation." "eGenesis is leading a field with the potential to transform the future of transplantation," added Dr. Craig. "I look forward to supporting the company's mission to develop safe, effective, human-compatible organs that could redefine the treatment of organ failure and offer hope to millions of patients awaiting a transplant." Drs. Williams and Craig join current Board members Steven Gillis, Ph.D. (Board Chairman), Bob More, Fabio Pucci, Ph.D., Brad Smith, Julie Sunderland, and Albert (Al) Wiegman. About eGenesis eGenesis is pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. Its platform uniquely addresses cross-species molecular incompatibilities and viral risk via its proprietary genetic engineering platform to improve outcomes for patients in need of a transplant. With demonstrated preclinical success, eGenesis is advancing programs in kidney transplantation, acute liver failure, and heart transplantation. Learn more at Follow us @egenesisbio. View source version on Contacts MediaKimberly Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store